Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
Sir Jony Ive, the British designer credited with shaping the iPhone and other iconic Apple products, is returning to the heart of Silicon Valley’s innovation scene – and this time, he may be aiming to disrupt the very device he helped make indispensable.
Six years after leaving Apple, Ive has partnered with OpenAI chief executive Sam Altman in a bold new venture. OpenAI has announced the acquisition of IO, a start-up founded by Ive, in an all-share deal reportedly worth $6.5 billion (£4.9 billion). The move marks a major step for the artificial intelligence company, as it seeks to expand beyond software and into consumer hardware.
While Ive will not become a full-time employee at OpenAI, he will serve as a consultant. IO’s 60-strong team of designers and engineers, many of whom are former Apple staff, will now work under the OpenAI umbrella. Their mission is to “reimagine what it means to use a computer”, with the help of ChatGPT and other AI tools developed by the company.
Altman has shared few specifics about what the first product will look like, but he has suggested it will not be a traditional smartphone or even include a screen. Instead, he and Ive plan to build a “family of devices” that could serve as intelligent companions, enhancing and potentially replacing the functions of a smartphone.
One potential outcome is a compact AI “pod” designed to work alongside existing gadgets like laptops or phones. OpenAI reportedly hopes to launch the first device by 2026 and eventually sell up to 100 million units. These devices could be offered through a subscription model linked to ChatGPT.
Ive, born in Essex and educated in industrial design in Newcastle, played a pivotal role at Apple from the 1990s onwards, creating the design language for products such as the iMac, iPod, iPhone and MacBook. His work, in close collaboration with the late Steve Jobs, helped transform Apple from a struggling tech firm into one of the world’s most valuable companies.
Jobs once described Ive as his “spiritual partner” at Apple, and said he held more power at the company than any other executive apart from himself. After Jobs’s death in 2011, Ive was widely viewed as Apple’s most influential figure until his departure in 2019.
Since leaving Apple, Ive has led his design consultancy LoveFrom, which has worked with high-profile clients including Ferrari and contributed to ceremonial design elements for the King’s Coronation. But he has also voiced disillusionment with the modern tech industry, criticising the dominance of “corporate agendas” focused on money and power.
In his new collaboration with Altman, Ive sees a return to what he calls “trying to move things forward”. He said, “Everything I have learnt over the last 30 years has led me to this place and to this moment.”
Despite the buzz surrounding the deal, some analysts have expressed scepticism. Technology analyst Richard Windsor called Ive “the most expensive consultant in history”, warning that the consultancy arrangement could allow him to quietly exit the partnership if it falters. Others have raised concerns about the valuation placed on IO and questioned whether the move is another sign of an AI investment bubble.
OpenAI is currently one of the most prominent players in the artificial intelligence race, valued at $300 billion and backed by Microsoft. The company has committed to building artificial general intelligence (AGI) and is investing heavily in data centres and infrastructure. In March, it raised $40 billion to fund these ambitions.
The new hardware project follows a string of unsuccessful attempts by others to challenge the smartphone’s dominance. Start-ups like Humane and Rabbit have launched compact AI-driven devices but failed to gain traction. Ive has criticised these efforts, calling them “very poor products”.
Meanwhile, tech giants such as Meta and Apple have explored wearable devices like AI-powered glasses and augmented reality headsets, but adoption remains limited. Analysts say consumers have been slow to embrace such technologies, and the market remains difficult to crack.
Still, the combination of Altman’s AI expertise and Ive’s design credentials has generated significant interest. “Jony did the iPhone, Jony did the MacBook Pro,” Altman said. “These are the defining ways people use technology.”
Whether this new venture can redefine consumer tech once again remains to be seen, but many in the industry believe that with Jony Ive involved, it is not a possibility to be dismissed lightly.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.